Inclusion Criteria:

          1. Patients with c-KIT mutated histologically proven advanced mucosal or acral melanoma
             in which the mutation is not known to be associated with nilotinib resistance.

          2. Advanced mucosal and acral melanoma defined as unresectable locally advanced or
             metastatic disease

          3. The presence of one or more clinically or radiologically measurable lesions at least
             10mm in size

          4. Age 18 or greater

          5. ECOG performance status 0, 1 or 2

          6. Life expectancy greater than 12 weeks

          7. At least 14 days since any major surgery

          8. The capacity to understand the patient information sheet and ability to provide
             written informed consent

          9. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests and other study procedures

         10. Women must not be pregnant or lactating with no intention of pregnancy during study
             treatment. Women of child bearing potential must have a negative serum pregnancy test
             prior to study entry (even if surgically sterilised). Men and women of childbearing
             potential must use adequate birth control measures (e.g. abstinence, oral
             contraceptives, intrauterine device, barrier method with spermicide, implantable or
             injectable contraceptives or surgical sterilisation) for the duration of the study and
             should continue such precautions for 6 months after receiving the last study treatment

         11. Serum alanine transaminase (ALT) or serum aspartate aminotransferase ≤2.5 x upper
             limit of normal (ULN) and total serum bilirubin ≤1.5 x ULN

         12. Serum creatinine ≤1.5 x ULN

         13. Serum lipase and amylase <1.5 x ULN

         14. Haemoglobin ≥9.0 g/dL, absolute neutrophil count ≥1.5 x 109/L, platelets ≥100 x 109/L

         15. Prothrombin time (PT) ≤1.5 x ULN

         16. Able to swallow and retain oral medication.

        Exclusion Criteria:

          1. Intracranial disease, unless there has been radiological evidence of stable
             intracranial disease > 6 months. In the case of a solitary brain metastasis, evidence
             of a disease-free interval of at least 3 months post surgery. All patients previously
             treated for brain metastases must be stable off corticosteroid therapy for at least 28
             days

          2. Women who are pregnant, nursing, or planning to become pregnant during the course of
             the trial

          3. Men who plan to father a child during the course of the trial

          4. Use of any investigational drug within 30 days prior to screening (both cancer and non
             cancer treatments)

          5. Use of herbal or chinese medication

          6. Use of therapeutic coumarin derivatives (ie warfarin, acenocoumarol, phenprocoumon)

          7. Significant cardiac disease including patients who have or who are at significant risk
             of developing prolongation of QTc

          8. Severe and/or uncontrolled medical disease

          9. Known chronic liver disease

         10. Past medical history of chronic pancreatitis

         11. Known HIV infection

         12. Previous radiotherapy to 25% or more of the bone marrow

         13. Radiation therapy in the 4 weeks prior to study entry

         14. Prior exposure to a tyrosine kinase inhibitor

         15. Known lactose intolerance

         16. Any malabsorption syndrome (i.e. partial gastrectomy, small bowel resection, Crohn's
             disease or ulcerative colitis).